Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on October 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard E Lowenthal, the President and CEO of ARS Pharmaceuticals, sold 100,000 shares of the company's common stock on October 8, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• The shares were sold in two transactions at weighted average prices of $13.8277 and $13.8278.
• Following the transactions, Lowenthal directly owns 4,315,313 shares.
• Lowenthal also has indirect ownership through various trusts, including the Richard Lowenthal Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and the Sarina Tanimoto Charitable Remainder UniTrust, as well as spousal holdings.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports a stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on inside information. The market typically views these sales in the context of the insider's overall holdings and the reasons behind the sale.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.
• The sale does not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates